Stevens Capital Management LP acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,151 shares of the company’s stock, valued at approximately $667,000.

Several other large investors also recently bought and sold shares of IONS. Prudential Financial Inc. increased its stake in shares of Ionis Pharmaceuticals by 36.4% in the 1st quarter. Prudential Financial Inc. now owns 8,241 shares of the company’s stock worth $331,000 after purchasing an additional 2,200 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Ionis Pharmaceuticals by 6.3% in the 1st quarter. Teachers Advisors LLC now owns 131,656 shares of the company’s stock worth $5,293,000 after purchasing an additional 7,846 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Ionis Pharmaceuticals by 211.2% in the 1st quarter. Legal & General Group Plc now owns 40,536 shares of the company’s stock worth $1,630,000 after purchasing an additional 27,512 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Ionis Pharmaceuticals by 75.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 170,316 shares of the company’s stock worth $6,847,000 after purchasing an additional 72,975 shares in the last quarter. Finally, Aperio Group LLC increased its stake in shares of Ionis Pharmaceuticals by 3.4% in the 2nd quarter. Aperio Group LLC now owns 17,656 shares of the company’s stock worth $898,000 after purchasing an additional 574 shares in the last quarter. Hedge funds and other institutional investors own 88.98% of the company’s stock.

In other news, CEO Stanley T. Crooke sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $52.00, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now owns 43,014 shares in the company, valued at $2,236,728. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,636 shares of company stock valued at $5,890,085. Company insiders own 2.13% of the company’s stock.

Several equities research analysts have recently commented on IONS shares. Stifel Nicolaus restated a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price objective for the company in a research note on Tuesday, October 17th. BMO Capital Markets restated an “outperform” rating and issued a $62.00 price objective (up from $59.56) on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 25th. Barclays PLC started coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group, Inc. restated a “sell” rating and issued a $30.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $50.31.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $54.36 on Friday. The firm has a market capitalization of $6,695.28, a PE ratio of 357.67 and a beta of 2.90. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals, Inc. has a 12-month low of $37.26 and a 12-month high of $65.51.

WARNING: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/11/17/stevens-capital-management-lp-invests-667000-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.